Miller JS - Search Results

1

Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.

Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ. Markova M, et al. Among authors: miller js. Bone Marrow Transplant. 2007 Feb;39(4):193-9. doi: 10.1038/sj.bmt.1705556. Epub 2007 Jan 15. Bone Marrow Transplant. 2007. PMID: 17220905 Clinical Trial.

2

Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy.

Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P. Miller JS, et al. Bone Marrow Transplant. 1994 Oct;14(4):555-62. Bone Marrow Transplant. 1994. PMID: 7532064

3

Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF.

Weisdorf DJ, Verfaillie CM, Davies SM, Filipovich AH, Wagner JE Jr, Miller JS, Burroughs J, Ramsay NK, Kersey JH, McGlave PB, et al. Weisdorf DJ, et al. Among authors: miller js. Blood. 1995 Jun 15;85(12):3452-6. Blood. 1995. PMID: 7540062 Free article. Clinical Trial.

4

Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients.

Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A, Miller W, Weisdorf D. Ochs L, et al. Blood. 1995 Nov 15;86(10):3979-86. Blood. 1995. PMID: 7579369 Free article. Review.

5

Chronic myelogenous leukemia: in search of the benign hematopoietic stem cell.

McGlave P, Verfaillie C, Miller J. McGlave P, et al. Stem Cells. 1993 Oct;11 Suppl 3:10-3. doi: 10.1002/stem.5530110905. Stem Cells. 1993. PMID: 7905318 Review.

6

Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy.

Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Miller JS, et al. Among authors: miller wj. Blood. 1994 Jun 15;83(12):3780-6. Blood. 1994. PMID: 8204897 Free article.

7

Malignant neoplasms following bone marrow transplantation.

Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, Neglia JP. Bhatia S, et al. Among authors: miller js. Blood. 1996 May 1;87(9):3633-9. Blood. 1996. PMID: 8611687 Free article.

8

Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.

Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W, Ramsay NK, Arthur D, Verfaillie C, Miller J, Kersey J, McGlave P. Enright H, et al. Blood. 1996 Jul 15;88(2):714-20. Blood. 1996. PMID: 8695820 Free article.

9

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J Jr, Burns LJ. Miller JS, et al. Biol Blood Marrow Transplant. 1997 Apr;3(1):34-44. Biol Blood Marrow Transplant. 1997. PMID: 9209739 Clinical Trial.

10

Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.

Miller JS, Tessmer-Tuck J, Blake N, Lund J, Scott A, Blazar BR, Orchard PJ. Miller JS, et al. Exp Hematol. 1997 Oct;25(11):1140-8. Exp Hematol. 1997. PMID: 9328450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,141 results

Search Page

Filters